Vimarsana
Biggest News Aggregation in the World

Clinical Assets News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Assets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Assets Today - Breaking & Trending Today

WELL Health Technologies Corp. completed the acquisition of Significant Portion of Clinical Assets of MCI Medical clinics Inc. - Vimarsana News

WELL Health Technologies Corp. completed the acquisition of Significant Portion of Clinical Assets of MCI Medical clinics Inc.

WELL Health Technologies Corp. entered into an agreement to acquire Significant Portion of Clinical Assets of MCI Medical clinics Inc. on July 19, 2023. The acquisition brings more than 130...

WELL Health Technologies Corp. entered into an agreement to acquire Significant Portion of Clinical Assets of MCI Medical clinics Inc. - Vimarsana News

WELL Health Technologies Corp. entered into an agreement to acquire Significant Portion of Clinical Assets of MCI Medical clinics Inc.

WELL Health Technologies Corp. entered into an agreement to acquire Significant Portion of Clinical Assets of MCI Medical clinics Inc. on July 19, 2023. The acquisition brings more than 130...

WELL Health Acquires EMR, Billing, Clinical Assets from CloudMD for $5.75M - Vimarsana News

WELL Health Acquires EMR, Billing, Clinical Assets from CloudMD for $5.75M

WELL Health is acquiring CloudMD's Cloud Practice entity which includes OSCAR1 based Juno EMR and ClinicAid billing Software apps as well

Insilico Medicine appoints Dr. Feng Ren as co-CEO - Vimarsana News

Insilico Medicine appoints Dr. Feng Ren as co-CEO

Dr. Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is named co-CEO of Insilico Medicine Highlights: Insilico Medicine is a global, end-to-end, fully-integrated AI-powered biotechnology company with three business models: AI platform, collaboration, and internal pipeline. It utilizes AI and a fully distributed, highly parallel discovery model to rapidly develop its own drugs. Since 2021, the company has nominated 8 preclinical candidates and reached Phase I clinical trials with an AI-discovered and AI-designed molecule. It is also developing a set of AI pla...